Table 1.
Parameter | This study | ||
---|---|---|---|
Phenotype | Series A | Series Ba | Series A+B |
No of cases | |||
Patients | 39 | 54 | 93 |
Tumors | 40 | 56 | 96 |
Samples studied | |||
Blood/normal tissues | – | 5 | |
Primary tumors | 38 | 54 | 92 |
Metastases | 2 | 2 | 4 |
Gender | |||
Female | 20 | 31 | 51 |
Male | 18 | 23 | 41 |
Age at diagnosis | |||
Range (years) | 17–81 | 13–77 | 13–81 |
Syndrome/mutation | |||
SDHB | 6 | 4 | 10 |
MEN2/RET | 9 | 3 | 12 |
NF1 | 5 | 2 | 7 |
VHL/VHL | 2 | 1 | 3 |
Diagnosis | |||
Pheochromocytoma | 27 | 43 | 70 |
Paraganglioma | 12 | 11 | 23 |
Metastasized | 7 | 7 | 14 |
Without metastasis | 32 | 47 | 79 |
Bilateral/multiple | 7 | 6 | 13 |
Survival | |||
DOD | 4 | 2 | 6 |
DOC | 7 | 6 | 13 |
A | 27 | 45 | 72 |
DOD, dead of disease; DOC, dead of other cause; A, alive, no reported disease.
Data for tumors from Geli et al. (2008) and Kiss et al. (2008).